There will soon be three PD-(L)1 x VEGF projects in pivotal lung and colorectal cancer trials.
ApexOnco Front Page
Recent articles
The Fortitude-102 trial, testing a bemarituzumab/Opdivo/chemo triplet, has failed.
Tough equity markets as well as competitor developments prompt a narrowed focus.
Another SERD catalyst and the son of Darzalex take centre stage.
Giredestrant will soon become the first oral SERD to yield first-line data.
The company hits an FDA-mandated enrolment target, but only in follicular lymphoma.
But this adds another complexity, and has camizestrant really scored a first-line win?
The company is starting a phase 3 trial of sacituzumab tirumotecan in first-line TNBC.
